ClinicalTrials.gg
Drug

Aflibercept clinical trials

Also written Eylea, Zaltrap, VEGF Trap and AVE0005.

studies test it
267
open now
11
in phase 3
59
first study started
2001

How each study uses aflibercept is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the aflibercept studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
18 Nov 2011 · EYLEA · BLA 125387 (FDA, Drugs@FDA)
European Union
21 Nov 2012 · Eylea · EMEA/H/C/002392 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Aflibercept
106
ziv-aflibercept
29
vascular endothelial growth factor trap
22
Intravitreal Aflibercept Injection
14
Aflibercept Injection
12

Brand

Eylea
80
Zaltrap
33
Eylea HD
2
Eylea 2mg
1

Development codes

VEGF Trap
23
AVE0005
12
BAY86-5321
10
ABP 938
2
SOK583A1
1

Other names

VEGF Trap-Eye
7

In one entry with another drug

Given together, or one or the other

Aflibercept + FOLFIRI
2

Biosimilars

PAVBLU™
1
Aflibercept-mrbb
1

Studies by the year they started

266 studies that test it; most in 2013 (28)

Studies that test aflibercept, by start year
YearStudies
20011
20021
20042
20051
200611
200715
20087
20097
20102
20114
201221
201328
201427
201527
201622
201716
201813
201914
202010
20218
20226
20232
20249
20254
20268

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
38
Phase 2
94
Phase 3
59
Phase 4
79
No phase
16

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 87 · Other 180

Regeneron Pharmaceuticals (25) · Bayer (22) · Sanofi (20) · National Cancer Institute (NCI) (18) · Unity Health Toronto (4) · Kim's Eye Hospital (3) · Singapore National Eye Centre (3) · Amgen (3)

Often tested with

Tested in the same studies.

Ranibizumab (14) · Bevacizumab (5) · FOLFIRI-Ziv-aflibercept Regimen (4) · FOLFIRI Regimen (4) · Docetaxel (3) · Fluorouracil (2) · Capecitabine (2) · Verteporfin (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 25 phase 3 studies under way

Aflibercept is the comparator. A study of two new drugs counts under both.

  • 4Vorolanib · EyePoint Pharmaceuticals, Inc. · next primary completion Oct 2027
  • 3OLN324 · Ollin Biosciences, Inc. · next primary completion Dec 2028
  • 2Axitinib · Ocular Therapeutix, Inc. · next primary completion Jan 2027
  • 2EYE201 · EyeBiotech Ltd. · next primary completion Jun 2028
  • 2RC28-E protein · RemeGen Co., Ltd.
  • 1Tarcocimab tedromer · Kodiak Sciences Inc
  • 1IBI302 · Innovent Biologics (Suzhou) Co. Ltd. · next primary completion Feb 2027
Reaching primary completion within a year · 3, 1 in phase 3

Studies that test aflibercept, phase 3 first.

Studies

Open first, then newest update. How each study uses aflibercept is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 267

See all 267 studies that test aflibercept →

Given beside what is tested · 52 — aflibercept is usual care or a partner of the new treatment

Showing 20 of 52.

As the comparator · 90 — what is tested is compared with aflibercept

Showing 20 of 90.

Codes

What other systems call aflibercept · ClinicalTrials.gg INT005352

  • MeSH (NLM) C533178afliberceptConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 15C2VL427DAFLIBERCEPTConfirmed FDA, NLM
  • RxNorm 1304475One source FDA
  • NCI Thesaurus C2682Ziv-AfliberceptOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.